Engraftment and outcomes of patients receiving myeloablative therapy followed by autologous peripheral blood stem cells with a low CD34+ cell content

Bone Marrow Transplantation

Volumn 19, Issue 11, 1997, Pages 1103-1110

  Weaver, C H ^a   Potz, J ^a   Redmond, J ^a   Tauer, K ^a   Schwartzberg, L S ^a   Kaywin, P ^a   Drapkin, R ^a   Grant, B ^a   Unger, P ^a   Allen, C ^a   Longin, K ^a   Zhen, B ^a   Hazelton, B ^a   Buckner, C D ^a,b  

^a Response Oncology Inc   (United States)

^b Response Oncology Inc   (United States)

Author keywords

Engraftment; Low CD34+ cells

Indexed keywords

ANTINEOPLASTIC AGENT; CD34 ANTIGEN; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; BLOOD CELL COUNT; BONE MARROW SUPPRESSION; CELL COUNT; CONDITIONING; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPHIL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; THROMBOCYTE COUNT;

EID: 0030908074     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700808     Document Type: Article

References (33)

1. Schwartzberg L, Birch R, Blanco R et al. Rapid and sustained hematopoietic reconstitution by peripheral blood stem cell infusion alone following high-dose chemotherapy. Bone Marrow Transplant 1993; 11: 369-374.
2. Sutherland HJ, Eaves CJ, Lansdorp PM et al. Kinetics of committed and primitive blood progenitor mobilization after chemotherapy and growth factor treatment and their use in autotransplants. Blood 1994; 83: 3808-3814.
3. Bensinger WI, Longin K, Appelbaum F et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony-stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994; 87: 825-831.
4. Bensinger W, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547-2555.
5. Weaver CH, Hazelton B, Birch R et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-3969.
6. Haas R, Möhle R, Frühauf S et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787-3794.
7. Demirer T, Bensinger WI. Optimization of peripheral blood stem cell collection. Curr Opin Hematol 1995; 2: 219-226.
8. Tricot G, Jagannath S, Vesole D et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588-596.
9. The American Society of Clinical Oncology and American Society of Hematology recommended criteria for the performance of bone marrow transplantation. J Clin Oncol 1990; 8: 563-564.
10. Weaver CH, Schwartzberg LS, Hainsworth J, Greco FA. Treatment related mortality in 1000 consecutive patients receiving high-dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centers. Bone Marrow Transplant 1997; 19: 671-678.
11. Schwartzberg L, Birch R, Hazelton B et al. Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor. J Hematother 1992; 1: 317-327.
12. Weaver C, Birch R, Schwartzberg L, West W. High-dose chemotherapy and autologous stem cell transplantation for breast cancer. In: Buckner CD, Clift R (eds). Technical and Biological Component of Marrow Transplantation. Kluwer Academic: Boston, MA, 1995, pp 59-85.
13. Weaver CH, West WH, Schwartzberg LS et al. Induction, mobilization of peripheral blood stem cells (PBSC), high-dose chemotherapy and PBSC infusion in patients with untreated stage IV breast cancer: outcomes by intent to treat analyses. Bone Marrow Transplant 1997; 19: 661-670.
14. Weaver CH, Bensinger WI, Appelbaum FR et al. Phase I study of high-dose busulfan, melphalan, thiotepa with autlogous stem cell support in patients with refractory malignancies. Bone Marrow Transplant 1994; 14: 813-819.
15. Schiffman KS, Bensinger WI, Appelbaum FR et al. Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease. Bone Marrow Transplant 1996; 17: 943-950.
16. Weaver CH, Schwartzberg LS, Li W et al. High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease. Bone Marrow Transplant 1996; 17: 715-721.
17. Cunningham D, Paz-Ares L, Milan S et al. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 1994; 12: 759-763.
18. Tutschka PJ, Copeland EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382-1388.
19. Demirer T, Buckner CD, Appelbaum FR et al. High-dose busulfan and cyclophosphamide followed by autologous transplantation in patients with advanced breast cancer. Bone Marrow Transplant 1996; 17: 769-774.
20. Weaver CH, Wittlin F, Lewis M et al. A phase I trial of high-dose melphalan, mitoxantrone and carboplatin in patients with ovarian and breast cancer. Proc Am Soc Hematol 1995; 86: 973a (Abstr.).
21. Elias AD, Ayash LJ, Wheeler C et al. Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support. Bone Marrow Transplant 1995; 15: 373-379.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
23. Shimazaki C, Oku N, Uchiyama H et al. Effect of granulocyte colony-stimulating factor on hematopoietic recovery after peripheral blood progenitor cell transplantation. Bone Marrow Transplant 1994; 13: 271-275.
24. Spitzer G, Adkins DR, Spencer V et al. Randomized study of growth factors post-peripheral blood stem cell transplant: neutrophil recovery is improved with modest clinical benefit. J Clin Oncol 1994; 12: 661-670.
25. Klumpp TR, Mangan KF, Goldberg SL et al. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral blood stem cell transplantation: a prospective, randomized trial. J Clin Oncol 1995; 13: 1323-1327.
26. Cortelazzo S, Viero P, Bellavita P et al. Granulocyte colony-stimulating factor following peripheral blood progenitor cell transplant in non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 935-941.
27. Hill RS, Mazza P, Amos D et al. Engraftment in 86 patients with lymphoid malignancy after autologous marrow transplantation. Bone Marrow Transplant 1989; 4: 69-74.
28. Lindemann A, Herrmann F, Oster W et al. Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy. Blood 1989; 74: 2644-2651.
29. Bensinger WI, Price, TH, Dale DC et al. The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood 1993; 81: 1883-1888.
30. Nash RA, Schuening FG, Seidel K et al. Effect of recombinant canine granulocyte-macrophage colony-stimulating factor on hematopoietic recovery after otherwise lethal total body irradiation. Blood 1994; 83: 1963-1970.
31. O'Malley CJ, Rasko JEJ, Basser RL et al. Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation. Blood 1996; 88: 3288-3298.
32. Grossmann A, Lenox J, Deisher T et al. Synergistic effects of thrombopoietin and granulocyte colony-stimulating factor on neutrophil recovery in myelosuppressed mice. Blood 1996; 88: 3363-3370.
33. + cells in engraftment after high-dose melphalan in multiple myeloma patients given peripheral blood stem cell rescue. Bone Marrow Transplant 1996; 18: 871-878.